Enrolling by invitationPHASE1, PHASE2NCT04432623
The BENeFiTS Trial in Beta Thalassemia Intermedia
Studying Beta-thalassemia intermedia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Phoenicia BioScience
- Principal Investigator
- Susan Perrine, MD, MDPhoenicia BioScience
- Intervention
- Benserazide Only Product(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (5)
- UCSF Benioff Children's Hospital at Oakland, Oakland, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Susan Perrine, Weston, Massachusetts, United States
- Weil Cornell Medicine, New York, New York, United States
- University Health Network and Toronto General Hospital, Toronto, Ontario, Canada
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04432623 on ClinicalTrials.gov